Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
On May 5, 2020, Athersys announced that the first patients have been enrolled in Athersys’ pivotal Phase 2/3…